Calls for papers
-
Aegis Therapeutics has received US Patent No. 7,998,927 for stabilized formulations of GLP-1 peptide analogs that can be delivered by a variety of different routes, including intranasal. All currently available GLP-1 formulations, which can control… Read more . . .
-
NexBio, which was recently raided by the US Federal Bureau of Investigation (FBI), has announced results from a Phase 2 clinical trial of its Fludase inhaled antiviral for the treatment of influenza. According to the… Read more . . .
-
Massacheusetts biotech company Pulmatrix has secured $14 million in additional funding from its existing investors, including Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, and Novartis Venture Fund, bringing its total to $60 million. Terry… Read more . . .
-
The United States Patent and Trademark Office (USPTO) has issued US Patent No. 7,994,197, titled “Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile,” to MAP Pharmaceuticals for its… Read more . . .
-
A leading pharmaceutical company has an exciting opportunity for an experienced device engineer. This position is based in Switzerland. In this role you will: • Support and lead inhalation device development projects • Mentor fellow… Read more . . .
-
After a meeting with the FDA, MannKind Corporation has announced that the company and the agency have confirmed protocols for new efficacy and safety studies of Afrezza inhaled insulin. The original studies of Afrezza were… Read more . . .
-
Akela Pharma is looking for a buyer for its Taifun fentanyl development program after Teikoku Seiyaku returned Japanese rights to the product. The dry powder inhaler (DPI) was being developed for the treatment of breakthrough… Read more . . .
-
MAP Pharmaceuticals has hired Frederick H. Graff as VP, Commercial Operations, a position newly created in anticipation of a potential launch of the company’s Levadex inhaled dihydroergotamine (DHE) for the treatment of migraine. Graff was… Read more . . .
-
On or about September 6, 2011, United States District Court Judge William G. Young will hold a hearing to issue sanctions against InnovaSystems for contempt of court, having ruled that Innova has violated a permanent… Read more . . .
-
The US FDA has accepted the new drug application (NDA) filed by Teva on May 24, 2011 for its beclomethasone dipropionate (BDP) hydrofluoroalkane nasal spray for the treatment of seasonal allergic rhinitis (SAR) and perennial… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland